Abeona Therapeutics® Announces Date of Fourth Quarter / Full Year 2025 Financial Results and Participation in Upcoming 2026 Leerink Global Healthcare Conference
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) announced a conference call for its Q4 and full year 2025 results on Tuesday, March 17, 2026 at 8:30 a.m. ET, available by phone and webcast.
Management will also participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on March 10, 2026 at 8:40 a.m. ET; both webcasts will be archived for 30 days on the company’s Investors & Media events page.
Positive
- None.
Negative
- None.
News Market Reaction – ABEO
In the Mar 3 session, ABEO declined 2.37%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 09 | Inducement grants | Neutral | +0.0% | Restricted stock awards to new hires under Nasdaq inducement rules. |
| Dec 31 | Inducement grants | Neutral | +1.7% | Equity awards totaling 79,584 restricted shares for seven new employees. |
| Dec 15 | Executive appointment | Positive | -5.2% | Appointment of Chief Business Officer to lead strategy and business development. |
| Dec 11 | ZEVASKYN center | Positive | +0.9% | New Qualified Treatment Center in Texas for FDA-approved ZEVASKYN therapy. |
| Dec 08 | First ZEVASKYN use | Positive | +5.3% | First commercial patient treated with ZEVASKYN gene therapy for RDEB. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News tied to ZEVASKYN commercialization has coincided with positive price reactions, while a senior leadership hire saw a negative divergence.
Over the past few months, Abeona’s news flow has focused on ZEVASKYN commercialization and corporate development. The Dec 8, 2025 first commercial treatment and the Dec 11, 2025 new Qualified Treatment Center both saw positive reactions. In contrast, the Dec 15, 2025 Chief Business Officer appointment coincided with a -5.22% move. Recent inducement grant announcements in late 2025 and early 2026 produced muted-to-modest reactions. Today’s earnings date and conference participation notice fits into routine corporate communication rather than a major clinical or commercial milestone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, March 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Tuesday, March 17, 2026 at 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and corporate progress.
The conference call will be available via phone and webcast. To access the call, dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and Entry Code: 977217 five minutes prior to the start of the call. A live, listen-only webcast and archived replay of the call can be accessed on the Investors & Media section of Abeona’s website at https://investors.abeonatherapeutics.com/events. The archived webcast replay will be available for 30 days following the call.
Participation in 2026 Leerink Global Healthcare Conference
Abeona management will participate in a fireside chat at the 2026 Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 8:40 a.m. Eastern Time. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 30 days.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona AssistTM, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to successfully commercialize and market ZEVASKYN, including manufacturing sufficient batches of ZEVASKYN to meet demand; the therapeutic potential of ZEVASKYN; whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections by the FDA or other regulatory agencies, including those relating to preclinical programs and to the cGMP manufacturing of ZEVASKYN; the ability to achieve or obtain necessary regulatory approvals for our pre-clinical programs; the impact of any changes in the financial markets and global economic conditions, including those resulting from changes to U.S. trade policy, such as current or future tariffs; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise these forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com